Publications by authors named "M Dizbay"
Article Synopsis
- * Out of 90 RTR participants, the median antibody level was 16.7 AU/mL at 42 days post-first dose, with 60% showing positive serology; mycophenolic acid (MFA) and ACE inhibitors were found to decrease seropositivity.
- * Patients who received the Pfizer/BioNTech booster had better antibody levels and lower COVID-19 infections compared to those with the CoronaVac/Sinovac booster, indicating that heterologous vaccination is more effective for RTRs.
Objective: This study aimed to investigate the relationship between procalcitonin (PCT) kinetic and estimated glomerular filtration rates (eGFR) in critically ill patients who had Gram-negative primary bloodstream infection (GN-BSI) and responded to the antimicrobial therapy.
Materials And Methods: This single-centered study was retrospective and observational. Critically ill GN-BSI patients over 18 years old who had clinical and microbiological responses to antibiotic treatment were included in the study.
Background And Objectives: This study aimed to evaluate the frequency of multidrug-resistant (MDR) bacteria in biliary samples, MDR-bacteria risk factors, and the relationship between MDR-bacteria positivity and some clinical outcomes.
Materials And Methods: The study was conducted between May 2018 and May 2023, including patients over the age of 18 who had positive culture results in biliary samples. The frequency of MDR-bacteria in biliary samples was evaluated.
The effectiveness of antimicrobial photodynamic therapy on catheter infection model.
J Photochem Photobiol B
November 2024
Background/aim: This experimental study aimed to examine the effectiveness of transdermal antimicrobial photodynamic therapy (APDT) with and without antimicrobial lock therapy (ALT), on catheter biofilms.
Methods: S. epidermidis and C.
Background: The study aimed to compare polymyxin B with colistimethate sodium (CMS) regarding neurotoxicity, nephrotoxicity and 30-day mortality in patients with MDR Gram-negatives.
Methods: All adult patients who received polymyxin B or CMS for at least 24 h for the treatment of MDR microorganisms were evaluated retrospectively.
Results: Among 413 initially screened patients, 147 patients who were conscious and able to express their symptoms were included in the neurotoxicity analysis.